Despite walking away from Akorn, Kabi had a nice time as the number of marketed IV drugs has increased in the last three months (32 vs. 24). But the strong euro was stronger than expected and turned out to be a burden. Consensus was broadly met. Management generated a huge hullabaloo by all the adjustments (e.g. Veterans Affairs; IFRS 15 adoption), so one has to read all the footnotes carefully.
03 May 2018
Doors re-open, but operating CF melted away
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Doors re-open, but operating CF melted away
Fresenius SE & Co. KGaA (FRE:WBO) | 0 0 0.5% | Mkt Cap: 35,173m
- Published:
03 May 2018 -
Author:
Martin Schnee -
Pages:
3
Despite walking away from Akorn, Kabi had a nice time as the number of marketed IV drugs has increased in the last three months (32 vs. 24). But the strong euro was stronger than expected and turned out to be a burden. Consensus was broadly met. Management generated a huge hullabaloo by all the adjustments (e.g. Veterans Affairs; IFRS 15 adoption), so one has to read all the footnotes carefully.